7 results
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
- Pharmacology ... normally inactivates GLP ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
- Pharmacology ... ) Common Side Effects ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
to treat Type 2 Diabetes ... Common side effects ... #Pharmacology #Dosing ... #Diabetes #DM2 ... #Endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
GLP-1 Receptor Agonists ... - Pharmacology ... Receptor #Agonists #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
Increase Incretins (GLP-I ... titrate up to effects ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
, GLP-1 receptor ... α-glucosidase inhibitor ... #Mellitus #DM2 ... #Medications #pharmacology ... comparison #table #endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
SGLT2 Inhibitors ... class of anti-diabetic ... #Pharmacology # ... Medications #DM2 ... #Diabetes #Endocrinology